Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
rHu EPO More
rHu G-CSF More
Gastro Retentive Drug Delivery System More
Adult autologous myoblasts cell suspension More
A botanical drug, WH-1, has been approved for US FDA Phase II clinical trials for the treatment of diabetic foot ulcers and also potentially indicated for similar chronic wound healing management conditions. More
Cardiovascular physiology and atherosclerosis - prevention of cardiovascular complications in patients with renal failure or increased carbamylation. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Acute coronary syndromes
- Anemia
- Anticoagulants
- Blood clotting
- Blood composition
- Cardiovascular disorder (other)
- Cerebrovascular disorders
- Thrombotic disorders
- Treatments
- Vascular
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us